Liquidia Corporation, also referred to as LQDA, is a late-stage clinical biopharmaceutical company specializing in the innovation and development of various product candidates by using its proprietary technology named PRINT®. This acronym, PRINT, stands for Particle Replication in Non-wetting Templates, visualizing the company's focus on producing precisely engineered nanoparticles to improve the delivery and effectiveness of complex drugs.
Founded in 2004, Liquidia Corp is headquartered in Research Triangle Park, North Carolina. Its primary mission lies in leveraging the unique properties emerging from its ability to design and develop engineered particles. This approach is anticipated to dramatically enhance the safety, function, and performance of numerous therapeutic solutions, specifically in areas that have been limited by traditional technologies.
Liquidia's lead product candidate, called LIQ861, seeks to simplify the management of pulmonary arterial hypertension (PAH). The company expects LIQ861 to improve the therapeutic performance of the compound by using its PRINT technology to produce a dry powder spray formulated exclusively with particles small enough to reach the deep lung’s vasculature. In 2020, this product was under priority review by the U.S. Food and Drug Administration (FDA).
In addition to PAH, Liquidia's PRINT technology has been used to address several other therapeutic areas and paths, ranging from local therapies to systemic diseases. The company has entered numerous collaborations with other industry leaders to grow and empower its robust pipeline.
Liquidia Corp's strength arises from its unique, patented technology platform and the potential it offers to improve drug delivery across a wide variety of diseases. It also benefits from a strong leadership team with extensive industry expertise. Its enduring struggle to deliver better, more reliable medicines has positioned Liquidia Corp as an innovative player in the biopharmaceutical sector. And despite the risks associated with pharmaceutical development, the corporation's high potential in creating transformative therapies using its pioneering technologies has continued to attract keen interest from investors and industry specialists alike.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Liquidia (NASDAQ:LQDA) insider Jason Adair sold 688 shares of company stock for $29,714.72 to cover tax withholding obligations from vested equity awards, retaining 177,269 shares. The company's shares rose 0.6% to $45.72, and while revenue significantly increased year-over-year, earnings per share of $0.74 slightly missed analyst expectations. Liquidia currently holds a consensus "Hold" rating from analysts with an average price target of $72.85, and institutional investors own about 64.54% of the stock.
Liquidia Corporation (LQDA) saw its shares jump 5.7% to $45.06 on Monday, with a volume of 2.3M shares. The surge was noted in a Benzinga roundup of rising stocks, but no specific company-level catalyst, such as clinical trial results or financial updates, was publicly disclosed. This suggests the rally might be due to broader sector momentum or technical trading patterns rather than fundamental news specific to Liquidia.
Liquidia Corporation (NASDAQ:LQDA) saw its stock price surge by 6.3% to $36.27 on Tuesday after four Wall Street firms raised their price targets, indicating increased confidence in the company's future. The average new price target reached $57, suggesting significant potential upside. This bullish sentiment reflects optimism around Liquidia's commercial execution and pipeline, with analysts believing the current valuation undervalues its growth trajectory.
Liquidia's shares surged after settling six lawsuits with United Therapeutics, which had caused a significant plunge in its stock previously. The settlement includes Liquidia paying United Therapeutics $380.7 million, removing a PH-ILD indication from Yutrepia's label, and allows Liquidia to continue selling Yutrepia for PAH and developing other treprostinil formulations. Analysts are divided on which company benefited more from the settlement, with some seeing it as a win for Liquidia due to the removal of legal overhangs and others viewing it as a clear win for United Therapeutics for protecting its PH-ILD franchise and gaining significant sales from patient transitions.
Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending lawsuits between the companies. The agreement ensures that YUTREPIA (treprostinil) inhalation powder remains available for patients with pulmonary arterial hypertension (PAH) and allows Liquidia to focus on growing the brand. Liquidia will pay a total of $380.7 million across 2026 and 2027 as part of the settlement.
This week, Crocs (CROX) and Liquidia (LQDA) saw their stocks upgraded due to growth potential and resolved legal issues, respectively. In contrast, Albertsons (ACI) faced multiple downgrades due to business challenges and financial outlook concerns. Additionally, AT&T (T) and AST SpaceMobile (ASTS) were downgraded amid increasing competition from SpaceX in broadband and satellite-based phone services.
Shares of Liquidia (LQDA) recently dropped significantly after a federal judge ruled that its drug Yutrepia infringed on a United Therapeutics patent, despite a subsequent settlement. The article analyzes Liquidia's past market downturns and recovery times, noting its current strong operating margin and cash position. It also highlights potential future cost increases and provides investment strategies for LQDA.
Liquidia (NASDAQ:LQDA) was upgraded from a "market perform" to an "outperform" rating by Lifesci Capital, with a price target of $59, suggesting a 73.84% upside. This upgrade follows a significant 26.6% increase in Liquidia's stock price to $33.94. The company recently reported strong revenue growth but slightly missed earnings estimates, while institutional investors hold a majority stake and insiders have been selling shares.
Liquidia Corporation's stock jumped nearly 27% following the announcement of a global settlement with United Therapeutics, resolving all pending litigation. This settlement removes a significant cloud of legal uncertainty, which had previously impacted the stock. While opportunities for YUTREPIA's commercialization are enhanced, some risks remain regarding product adoption and the full impact of settlement terms on growth and valuation.